E
|
| E faecium, vancomycin-resistant (Table) |
|
 |
|
| Ear wax removal |
|
|
|
| Echinacea (Table) |
|
|
|
| Echinocandins (Table) |
|
|
|
| Echocardiography |
|
|
| in acute stroke |
|
|
| in AF |
|
|
| in aortic stenosis |
|
|
| in CAD |
|
|
|
| Echothiophate (Phospholine) (Table) |
|
|
|
| EC-Naprosyn (naproxen) (Table) |
|
|
|
| Econazole nitrate (Spectazole) (Table) |
|
|
|
| ECT (electroconvulsive therapy) |
|
|
| for depression |
|
|
| for severe or psychotic depression |
|
|
|
| Efavirenz (Table) |
|
|
|
| Effexor |
|
|
| See also Venlafaxine |
|
|
| prescribing information for depression (Table) |
|
|
| prescribing information for menopausal symptoms |
|
|
|
| Effexor XR |
|
|
| See also Venlafaxine |
|
|
| prescribing information for depression (Table) |
|
|
|
| Efudex (5-fluorouracil) |
|
|
|
| Elastic wraps |
|
|
|
| Elavil |
|
|
| See also Amitriptyline |
|
|
| avoid use |
|
|
|
| Eldepryl (selegiline) (Table) |
|
|
|
| Elder mistreatment |
|
|
| Elder Mistreatment section |
|
|
| resources for |
|
|
| signs that raise suspicion of (Table) |
|
|
|
| Electrical stimulation |
|
|
|
| Electrocardiography |
|
|
| absolute indications for hospitalization |
|
|
| and hyperkalemia |
|
|
|
| Electroconvulsive therapy |
|
|
| for depression |
|
|
| for severe or psychotic depression |
|
|
|
| Electrodessication |
|
|
|
| Electron-beam computed tomography (EBCT) (Table) |
|
|
|
| Electrosurgery |
|
|
|
| Electrovaporization |
|
|
|
| Elimite (permethrin) |
|
|
|
| Elocon (mometasone furoate) |
|
|
| prescribing information for dermatologic conditions (higher potency) (Table) |
|
|
| prescribing information for dermatologic conditions (mid-potency) (Table) |
|
|
|
| Eltroxin |
|
|
| See also Levothyroxine |
|
|
| prescribing information for hypothyroidism |
|
|
|
| Emadine (emedastine) (Table) |
|
|
|
| Embolism, pulmonary (PE) |
|
|
| Pulmonary Embolism section |
|
|
| anticoagulation for (Table) |
|
|
| anticoagulation in absence of active bleeding or severe bleeding risk (Table) |
|
|
| clinical decision rule for (Table) |
|
|
| evaluation of suspected PE (Figure) |
|
|
| medications for osteoporosis and (Table) |
|
|
| prophylaxis and treatment |
|
|
|
| Emedastine (Emadine) (Table) |
|
|
|
| Enablex |
|
|
| See also Darifenacin |
|
|
| prescribing information for UI (Table) |
|
|
|
| Enalapril (Vasotec) |
|
|
| prescribing information for HTN (Table) |
|
|
| prescribing information for hypertensive emergencies and urgencies |
|
|
| target dose in HF (Table) |
|
|
|
| Enalapril maleate with felodipine (Lexxel) (Table) |
|
|
|
| Enalapril maleate with HCTZ (Vaseretic) (Table) |
|
|
|
| Enbrel (etanercept) |
|
|
|
| Endocarditis prophylaxis |
|
|
| AHA Guidelines |
|
|
| perioperative |
|
|
| regimens (Table) |
|
|
|
| Endocrine disorders |
|
|
|
| End-of-life care |
|
|
| Palliative and End-of-Life Care chapter |
|
|
| resources for |
|
|
|
| Endovascular repair |
|
|
| for abdominal aortic aneurysm |
|
|
| for PAD (Table) |
|
|
|
| Enemas |
|
|
| for chronic constipation |
|
|
| for fecal incontinence |
|
|
| for fecal incontinence in nursing-home residents and very disabled elderly persons |
|
|
| prescribing information for constipation (Table) |
|
|
| prescribing information for hyperkalemia |
|
|
| prescribing information for hyperkalemia inpatient management |
|
|
| for rectal evacuation |
|
|
|
| Enemeez |
|
|
|
| Energy requirements |
|
|
|
| Energy supplements |
|
|
|
| Enjuvia (synthetic conjugated estrogen B) (Table) |
|
|
|
| Enlive (Table) |
|
|
|
| Enoxaparin (Lovenox) |
|
|
| prescribing information for acute coronary syndrome (Table) |
|
|
| prescribing information for DVT or PE prophylaxis and treatment (Table) |
|
|
|
| Ensure (Table) |
|
|
|
| Ensure Fiber with FOS (Table) |
|
|
|
| Ensure Plus (Table) |
|
|
|
| Entacapone (Comtan) |
|
|
| carbidopa-levodopa & entacapone (Stalevo) (Table) |
|
|
| prescribing information for Parkinson's disease (Table) |
|
|
|
| Enteral nutrition |
|
|
| drug interactions |
|
|
| lactose-free products (Table) |
|
|
| for malnutrition |
|
|
| for stress-ulcer prevention |
|
|
|
| Enterobacter |
|
|
| in noncatheterized patients |
|
|
| in nursing-home–catheterized patients |
|
|
|
| Enterococcus faecium, vancomycin-resistant (Table) |
|
|
|
| Environmental modification |
|
|
| for delirium |
|
|
| in end-of-life care |
|
|
| for preventing falls (Table) |
|
|
| for visual impairment |
|
|
|
| Epifrin |
|
|
| See also Epinephrine |
|
|
| prescribing information for glaucoma (Table) |
|
|
|
| Epinal (epinephrine borate) (Table) |
|
|
|
| Epinephrine (Epifrin, EpiPen, Glaucon) |
|
|
| for asthma and COPD (Table) |
|
|
| prescribing information for angioedema |
|
|
| prescribing information for glaucoma (Table) |
|
|
|
| Epinephrine borate (Epinal) (Table) |
|
|
|
| EpiPen |
|
|
| See also Epinephrine |
|
|
| for angioedema |
|
|
|
| Epival |
|
|
| See also Divalproex |
|
|
| prescribing information for agitation (Table) |
|
|
|
| Eplerenone (Inspra) |
|
|
| drug and metabolic interactions (Table) |
|
|
| prescribing information for HF |
|
|
| prescribing information for HTN (Table) |
|
|
|
| Epley's maneuver (Table) |
|
|
|
| Epoetin alfa (Epogen) (Table) |
|
|
|
| Epogen (epoetin alfa) (Table) |
|
|
|
| Eprosartan (Teveten) |
|
|
| prescribing information for HTN (Table) |
|
|
| target dosage in HF (Table) |
|
|
|
| Eprosartan mesylate with HCTZ (Teveten HCT) (Table) |
|
|
|
| Eptifibatide (Integrilin) (Table) |
|
|
|
| Epulor (Table) |
|
|
|
| Eraxis (anidulafungin) (Table) |
|
|
|
| Erectile dysfunction |
|
|
|
| Ergocalciferol (vitamin D2) |
|
|
|
| Ertrapenem (Invanz) |
|
|
| for community-acquired pneumonia (Table) |
|
|
| prescribing information for infectious diseases (Table) |
|
|
|
| Erysipelas |
|
|
|
| Erythrocyte sedimentation rate (ESR) |
|
|
|
| Erythroleukemia |
|
|
|
| Erythromycin |
|
|
| for cellulitis |
|
|
| for community-acquired pneumonia (Table) |
|
|
| digoxin interactions |
|
|
| drug and metabolic interactions (Table) |
|
|
| for erysipelas |
|
|
| for folliculitis |
|
|
| prescribing information (Table) |
|
|
| prescribing information for impetigo |
|
|
| prescribing information for rosacea (oral) |
|
|
| prescribing information for rosacea (topical) |
|
|
| tamoxifen interactions (Table) |
|
|
| and tinnitus |
|
|
|
| Erythromycin ophthalmic (AK-Mycin, Ilotycin) (Table) |
|
|
|
| Erythropoietin |
|
|
| for hypotension secondary to anemia |
|
|
| myelofibrosis |
|
|
| prescribing information for anemia associated with deficiency (Table) |
|
|
|
| Erythropoietin-darbopoetin |
|
|
|
| Escherichia coli |
|
|
|
| Escitalopram (Lexapro) |
|
|
| for anxiety disorders |
|
|
| prescribing information for depression (Table) |
|
|
|
| Eserine (physostigmine) (Table) |
|
|
|
| Esidrix (HCTZ) (Table) |
|
|
|
| Eskalith |
|
|
| See also Lithium |
|
|
| prescribing information for bipolar disorders (Table) |
|
|
|
| Eskalith CR |
|
|
| See also Lithium |
|
|
| prescribing information for bipolar disorders (Table) |
|
|
|
| Esmolol |
|
|
|
| Esomeprazole (Nexium) (Table) |
|
|
|
| Esophageal manometry |
|
|
|
| Esophageal procedures, endocarditis prophylaxis regimens (Table) |
|
|
|
| Esophagitis |
|
|
| medications for osteoporosis and (Table) |
|
|
| reflux esophagitis (Table) |
|
|
|
| ESR (erythrocyte sedimentation rate) |
|
|
|
| Essential thrombocytosis |
|
|
|
| Essential tremor |
|
|
| antihypertensive therapy and (Table) |
|
|
| classification of (Table) |
|
|
|
| Estazolam (ProSom) |
|
|
| daily dose thresholds (Table) |
|
|
| prescribing information for sleep disorders (Table) |
|
|
|
| Estrace |
|
|
| See also Estradiol |
|
|
| prescribing information for dyspareunia (Table) |
|
|
| regimen for systemic hormone therapy (Table) |
|
|
|
| Estraderm (transdermal estrogen) (Table) |
|
|
|
| Estradiol (Estrace) |
|
|
| drug and metabolic interactions (Table) |
|
|
| with norethindrone (CombiPatch) (Table) |
|
|
| with norethindrone (FEMHRT 1/5) (Table) |
|
|
| regimen for systemic hormone therapy (Table) |
|
|
| vaginal ring (Estring) (Table) |
|
|
| vaginal tablets (Vagifem) (Table) |
|
|
|
| Estradiol acetate (Femtrace) (Table) |
|
|
|
| Estrasorb (transdermal estrogen) (Table) |
|
|
|
| Estratab (estrogen) (Table) |
|
|
|
| Estring (estradiol vaginal ring) (Table) |
|
|
|
| EstroGel (transdermal estrogen) (Table) |
|
|
|
| Estrogen |
|
|
| with bisphosphonate or calcitonin |
|
|
| equine (Premarin) |
|
|
| prescribing information for agitation (Table) |
|
|
| prescribing information for dyspareunia (Table) |
|
|
| regimen for systemic hormone therapy (Table) |
|
|
| esterified (Estratab, Menest) (Table) |
|
|
| with medroxyprogesterone (Prempro, Premphase) (Table) |
|
|
| with progesterone |
|
|
| for hormone therapy |
|
|
| in postmenopausal bleeding |
|
|
| risks and benefits (Table) |
|
|
| synthetic (Cenestin) (Table) |
|
|
| synthetic conjugated B (Enjuvia) (Table) |
|
|
| transdermal (Alora, Bio-E-Gel, Estrasorb, Estraderm, Vivelle, Climara, FemPatch, EstroGel) |
|
|
|
| Estrogen therapy |
|
|
| Estrogen Therapy section |
|
|
| bone outcomes (Table) |
|
|
| for dyspareunia |
|
|
| effects on other outcomes, level of evidence, risks of (Table) |
|
|
| for menopausal symptoms |
|
|
| for osteoporosis prevention |
|
|
| for osteoporosis treatment |
|
|
| in postmenopausal bleeding |
|
|
| prescribing information for agitation (Table) |
|
|
| prescribing information for dyspareunia (Table) |
|
|
| for recurrent UTIs |
|
|
| regimens (Table) |
|
|
| risks and benefits (Table) |
|
|
| topical |
|
|
| for dyspareunia |
|
|
| prescribing information for dyspareunia (Table) |
|
|
| for recurrent UTIs |
|
|
| for UI |
|
|
| for vaginal prolapse |
|
|
|
| Estropipate (Ogen, Ortho-Est) |
|
|
| prescribing information for dyspareunia (Table) |
|
|
| regimen for systemic hormone therapy (Table) |
|
|
|
| Eszopiclone (Lunesta) |
|
|
| for anxiety |
|
|
| daily dose thresholds (Table) |
|
|
| prescribing information for sleep disorders (Table) |
|
|
|
| Etanercept (Enbrel) |
|
|
|
| Ethambutol |
|
|
| ocular adverse events |
|
|
| prescribing information for active tuberculosis (Table) |
|
|
| regimen for active tuberculosis |
|
|
|
| Ethnic groups |
|
|
|
| Etodolac (Lodine) |
|
|
| extended release (Lodine XL) (Table) |
|
|
| prescribing information for arthritis (Table) |
|
|
|
| Etretinate |
|
|
| for psoriasis |
|
|
| warfarin interactions |
|
|
|
| Eucerin |
|
|
|
| Euflexxa (hyaluronic acid) |
|
|
|
| Eulexin (flutamide) (Table) |
|
|
|
| Euthanasia |
|
|
|
| Euthyroid sick syndrome |
|
|
|
| Evista |
|
|
| See also Raloxifene |
|
|
| prescribing information for osteoporosis prevention |
|
|
| prescribing information for osteoporosis treatment |
|
|
|
| Exelon (rivastigmine) (Table) |
|
|
|
| Exemestane (Aromasin) (Table) |
|
|
|
| Exenatide (Byetta) (Table) |
|
|
|
| Exercise(s) |
|
|
| for back pain |
|
|
| for brain health |
|
|
| for chronic angina |
|
|
| for COPD |
|
|
| for delirium |
|
|
| for diabetes mellitus |
|
|
| for dyspnea |
|
|
| for fecal incontinence |
|
|
| for HTN |
|
|
| for low back pain syndrome |
|
|
| for metabolic syndrome |
|
|
| for nocturnal leg cramps |
|
|
| for osteoarthritis |
|
|
| for osteoporosis |
|
|
| for PAD |
|
|
| for pain management |
|
|
Index home